FWD Group Holdings Issuer Summary

Report date: 2026-05-13
Issuer: FWD Group Holdings Limited
Sector: Pan-Asian life and health insurance / insurance holding company
Primary credit focus: issuer credit, insurance financial strength of operating insurance subsidiaries, holding-company liquidity, and equity-credit/subordination features of subordinated dated capital securities

1. Business Snapshot and Recent Developments

FWD Group Holdings Limited (“FWD”) is an insurance holding company with a Hong Kong-listed pan-Asian life and health insurance group. For credit analysis, the starting point is not to view FWD simply as a growth insurer, but as a financial holding company that receives earnings, surplus capital and dividend remittances from insurance operating subsidiaries across multiple jurisdictions and uses them to support holding-company debt and subordinated capital securities. The insurance operating subsidiaries carry long-duration liabilities to policyholders and large investment assets, while holding-company creditors depend on remittances from those subsidiaries, regulatory capital headroom and access to capital markets. In analysing FWD, it is therefore important not to treat insurance sales growth, IFRS 17 CSM, embedded value, holding-company cash, subsidiary remittances and the ranking of subordinated capital securities as interchangeable.

FWD listed on the Main Board of the Hong Kong Stock Exchange on 7 July 2025 under stock code 1828. According to the 2025 Annual Report, the company operates in 10 Asian markets and serves more than 38 million customers. Its main markets include Hong Kong and Macau, Thailand and Cambodia, Japan, Indonesia, the Philippines, Singapore, Malaysia and Vietnam. The group offers life insurance, health insurance, general insurance, group insurance, investment-linked products and savings products. The company emphasises digital capabilities, customer experience and AI usage in its own description, but what bond investors should focus on first is not the digital profile itself, but whether this distribution platform converts into sustainable new business, CSM release, earnings and subsidiary remittances.

2025 was a milestone year for FWD’s issuer credit profile. First, the IPO improved the group’s access to capital markets as a listed company and increased the continuity of disclosure and financial flexibility for bond investors. Second, in September 2025, FWD issued US$575 million of five-year subordinated dated capital securities and US$575 million of 10-year subordinated dated capital securities, and redeemed existing US$900 million subordinated notes and US$750 million perpetual securities. Third, Moody’s upgraded FWD’s issuer rating to Baa1 in July 2025, while Fitch revised the group outlook to Positive in December 2025. Fourth, at end-2025, the group disclosed an LCSM cover ratio of 265% relative to the Prescribed Capital Requirement, and 210% on a pro forma basis after reflecting the introduction of Japan ESR, indicating regulatory capital headroom.

However, it would be risky to group these factors together mechanically as a simple credit improvement. The IPO is credit positive, but share price performance and market refinancing conditions do not always guarantee debt repayment capacity. The issuance of subordinated capital securities and redemption of old securities helped tidy up the capital structure and reduce leverage, but the newly issued securities are not senior debt; they have regulatory capital features, subordination and distribution-deferral terms. The 265% LCSM ratio is also strong, but the pro forma ratio falls to 210% after the transition of the Japanese subsidiary to the ESR regime, so apparent capital headroom should not be read as cash that can simply be used at will. The 2025 results reinforce the credit view, but for holding-company creditors it remains necessary to keep checking the path from subsidiary capital to holding-company cash.

The latest key indicators are as follows. Figures are based on the company’s 2025 annual results and Annual Report, with constant-exchange-rate growth rates following company disclosure.

In one sentence, FWD is “an insurance holding company with an Asian insurance franchise, but one whose credit assessment should distinguish between the financial strength of the insurance operating subsidiaries and the structural distance facing holding-company creditors.” Listing, capital restructuring, rating improvement and CSM growth are positive, but regional concentration of growth, ALM, the equity-credit features of subordinated securities and constraints on subsidiary remittances need to be assessed at the same time.

2. Industry Position and Franchise Strength

FWD’s business base is not that of a mature single-country life insurer, but a growth-oriented regional franchise spanning multiple Asian insurance markets. Asian life and health insurance markets benefit from long-term themes including rising incomes, protection gaps, medical cost inflation, ageing, retirement planning, digital distribution, bancassurance and wealth-transfer needs among high-net-worth customers. FWD captures this demand through country-specific insurance licences, bank, agency and digital channels, and policyholder bases acquired through acquisitions. The credit attraction lies in the potential to accumulate new business and future earnings while reducing dependence on any single market or product.

The elements supporting FWD’s franchise are customer scale, geographic diversification, distribution network, bancassurance, product breadth and digital operations. The 2025 Annual Report shows more than 38 million customers, 10 markets, 33 bancassurance partnerships and an agency force of more than 40,000. In Hong Kong and Macau, the group grew strongly in health, high-sum-assured protection and high-net-worth products. In Thailand, the relationship with Siam Commercial Bank is an important distribution base, while in Japan the group is expanding into savings products in addition to protection products. In emerging markets, Indonesia, the Philippines, Malaysia, Singapore and Vietnam provide long-term growth potential, supported by demographics, rising incomes and protection gaps.

However, FWD’s franchise should not be read as “large, therefore stable,” but rather as “offering growth potential, while requiring management of country-specific regulatory and product risks.” Sales growth builds future earnings, but it also involves commissions, guaranteed rates, lapses, medical claims, reinsurance and capital consumption. FWD is moving closer to becoming one of the major listed Asian insurance groups, but it is still at the stage where investors need to build evidence around CSM, LCSM free surplus, subsidiary remittances and holding-company liquidity.

The strength of FWD’s franchise is also visible in 2025 new business metrics. APE was US$2,446 million, up 25% year on year; new business CSM was US$1,476 million, up 18%; and VNB was US$945 million, up 11%. This indicates that new business origination capability remains intact, rather than merely reflecting organic growth in the in-force book. At the same time, VNB growth was lower than APE growth, and VNB declined year on year in Thailand & Cambodia and Japan, indicating that the quality of growth must be checked. APE, which is analogous to top-line sales, looks strong in isolation, but CSM and VNB, which reflect future profitability and capital consumption, show regional differences. FWD’s credit quality depends not only on sales volume, but on whether the group can continue writing profitable business.

In summary, FWD’s franchise strengths are its broad distribution network and growth potential across multiple markets. Its constraints are the complexity of country-specific regulation, insurance liabilities, investment assets, sales quality and subsidiary remittances. Bond investors should focus less on growth itself and more on whether that growth can be converted into distributable earnings for the holding company without excessive capital consumption.

3. Segment Assessment

In assessing FWD’s segments, it is necessary to distinguish between regional growth rates, margins and the quality of OPAT. In 2025, Hong Kong and Macau grew substantially and drove new business growth for the group as a whole. By contrast, Thailand & Cambodia recorded a decline in APE, new business CSM and VNB. Japan recorded growth in APE and new business CSM, but VNB and OPAT declined. Emerging Markets recorded APE growth, but growth in new business CSM and VNB was not as strong as APE growth. In other words, FWD’s 2025 growth was not a broad and uniform expansion; it involved different profitability and risk profiles by region.

Hong Kong and Macau are the largest contributors to the group across APE of US$1,207 million, new business CSM of US$684 million and VNB of US$478 million. Capturing demand for high-end medical, savings and high-net-worth products is clearly positive, but if a significant portion of new business value depends on one region, changes in Hong Kong interest rates, high-net-worth flows, medical costs, regulation, and bank or broker distribution can spill over to the whole group. Going forward, it will be important to track VNB margin, product-level profitability, claims ratios and the sustainability of high-net-worth sales in this region.

Thailand & Cambodia recorded a 6% decline in APE, a 16% decline in new business CSM and an 18% decline in VNB, while OPAT increased 18% to US$187 million. The existing book, expenses and investment income appear to be supporting earnings, while new business value creation faced headwinds from low interest rates and the exit from the corporate medical portfolio. From a credit perspective, it is necessary to distinguish whether the decline in new business value is a temporary effect of product remixing or a more structural weakness in distribution or profitability.

Japan is one of the markets that requires the most careful treatment in FWD’s credit analysis. In 2025, APE increased 11% and new business CSM increased 10%, but VNB declined 4% and OPAT declined 5%. In Japan, expansion from protection products into savings and wealth-accumulation products is progressing, but interest rates, hedging, ALM, guarantees embedded in insurance liabilities and ESR regulation have significant effects. The decline in the pro forma LCSM PCR to 210% after reflecting the introduction of Japan ESR shows that Japan’s regulatory capital measurement affects the view of group capital headroom. Japan cannot be assessed on sales growth alone without examining capital quality and ALM.

Emerging Markets recorded APE growth of 27% to US$529 million and represent a long-term growth option. However, OPAT remained only US$34 million. Demographics and protection gaps provide tailwinds, but the segment also carries risks around distribution regulation, currencies, legal enforcement, medical costs, reinsurance, political and regulatory changes, and subsidiary dividend constraints. For holding-company creditors, the focus is how much of the earnings can be remitted and how much capital is consumed.

The central point across the segments is that FWD’s growth is heavily supported by Hong Kong and Macau, while other regions show the effects of product mix and regulatory capital. Group-level APE, new business CSM and VNB are strong, but the regional dispersion is significant. For bond investors, what matters more than the overall growth rate is which regions generate capital, which consume capital and which can remit funds to the holding company. In the next update, country-level statutory profit, distributable amounts, solvency and remittance track record should be examined in more detail.

4. Financial Profile and Analysis

FWD’s financial profile needs to be assessed by combining post-IFRS 17 earnings improvement, growth in CSM and EV, regulatory capital headroom and holding-company liquidity. For insurers, single-year net profit alone is an incomplete measure of credit quality. New business sales can involve upfront costs, while future earnings are accumulated as CSM. Investment asset valuation gains and losses, as well as interest-rate movements, can also move accounting earnings. For FWD, APE and VNB growth should be read as indicators of business momentum, while CSM release, OPAT, NPAT, operating cash flow, group LCSM free surplus and holding-company remittances should be analysed separately.

The 2025 profit-and-loss and value indicators are as follows.

The positive points from this table are that post-IFRS 17 earnings improved and both CSM release and the CSM balance increased. The CSM balance of US$6.6 billion indicates the future earnings base of the in-force book, while the improvement to OPAT of US$499 million and NPAT of US$166 million suggests that FWD is moving into a more profitable phase.

At the same time, CSM and EV are not immediate resources for debt repayment. CSM is an accounting value recognised as profit in line with future service provision, and is affected by fulfilment of insurance liabilities, lapses, experience variance, interest rates, investment returns and regulatory capital. EV and CTE are also important value indicators, but interest and principal payments on holding-company bonds require actual remittances from operating subsidiaries, holding-company cash and refinancing access. The key analytical error to avoid in FWD’s credit analysis is to jump from growth in CSM or EV to the conclusion that repayment capacity has increased by the same amount.

The decline in operating cash flow to US$247 million in 2025 should also be analysed separately from earnings metrics. Accounting profit may improve, but the amount of cash reaching the holding company is a different question. Net remittances in 2025 were US$529 million, and holding-company liquidity was US$1,612 million. Group LCSM free surplus was US$4,833 million on a PCR basis, but this is not cash that can be freely remitted in full to the holding company. It should be assessed together with future growth investment, interest payments, redemptions and dividend policy.

On the balance sheet, financial investments and insurance contract liabilities are growing rapidly. At end-2025, total assets were US$62.4 billion, total liabilities were US$55.5 billion and total equity was US$6.9 billion. Financial investments were US$52.2 billion and insurance contract liabilities were US$49.7 billion. The essence of the insurance business is a structure in which long-duration liabilities collected from policyholders are supported by investment assets. FWD’s credit quality depends not only on operating growth, but also on investment asset quality, sensitivity to interest rates, foreign exchange and credit spreads, guarantees, duration and lapse features in insurance liabilities, reinsurance and ALM.

The 2025 improvement is positive, but the absolute level of earnings still cannot be described as particularly thick relative to insurance liabilities, investment assets and borrowings. NPAT of US$166 million is evidence of profitability, but sustained OPAT, subsidiary remittances and capital-market access are essential to support borrowings of more than US$3.0 billion, insurance contract liabilities of US$49.7 billion and regulatory capital across multiple markets.

In summary, FWD moved in 2025 from a growth-oriented insurance group closer toward an earnings and capital structure more typical of an investment-grade issuer. However, the credit assessment is still one of reading an improving business base together with complex insurance liabilities and a holding-company structure. The current financial profile supports issuer credit, but conservative bond analysis should centre on OPAT, group LCSM free surplus, remittances, liquidity, leverage and subordinated securities terms, rather than CSM or EV. Statutory profit, subsidiary-level distributable amounts, holding-company costs and annual interest expense have not been obtained in this report, so the repayment-resource bridge remains an initial assessment centred on near-term maturities and liquidity defences.

5. Insurance Liabilities, Investments and ALM

Insurance liabilities, investment assets and ALM are central to FWD’s credit analysis. An insurer’s credit quality is determined less by sales volume than by the assets used to support long-term obligations to policyholders, the extent to which those assets may be impaired under market stress, and the amount of regulatory capital they consume.

At end-2025, financial investments were US$52.2 billion and accounted for most of total assets. The portfolio includes debt securities, investment funds, equities, loans and deposits. Even if fixed-income assets are the core, the portfolio is affected by interest rates, credit spreads, issuer concentration, currency, hedging and duration, while investment funds and equities add valuation volatility and liquidity uncertainty.

Insurance contract liabilities were US$49.7 billion at end-2025. In medical and health insurance, medical inflation, unit treatment costs and claim frequency matter. In savings and investment-type products, guaranteed rates, interest rates, lapses and investment yields matter. In markets such as Japan where savings products are expanding, asset-liability management becomes more important alongside sales growth.

A key ALM issue is that the risk profile changes depending on the direction of interest-rate movements. Rising interest rates can create bond valuation losses and lapse pressure, while improving reinvestment yields. Falling interest rates can be positive for bond valuations, but may compress reinvestment yields relative to guaranteed rates on legacy products and long-duration liabilities. Widening credit spreads affect investment asset valuations and capital, while declines in equities and funds can move both earnings and other comprehensive income. The Annual Report sensitivities show that, at end-2025, a 10% decline in equity prices would have a negative impact of US$125 million on profit before tax and US$136 million on CSM. A 50bp rise in interest rates would have a positive impact of US$12 million on profit before tax, a negative impact of US$300 million on other components of equity and a positive impact of US$64 million on CSM. A 50bp decline in interest rates would have a negative impact of US$44 million on profit before tax, a positive impact of US$341 million on other components of equity and a negative impact of US$69 million on CSM. For the LCSM PCR cover ratio, end-2025 sensitivities show a negative 2ppt impact from a 10% equity decline, a negative 14ppt impact from a 50bp interest-rate increase and a positive 3ppt impact from a 50bp interest-rate decrease. Bond investors need to assess the duration, currency, guarantee and lapse characteristics of assets and liabilities together, rather than looking at each side separately.

The key regulatory capital focus areas for FWD are group LCSM and Japan ESR. At end-2025, the group LCSM cover ratio was 265% relative to PCR and 338% relative to MCR. This indicates substantial regulatory capital headroom. However, the company discloses that the pro forma PCR ratio falls to 210% after reflecting the introduction of Japan ESR. A 210% ratio still appears to leave meaningful headroom, but the decline from 265% should not be ignored. Japan is important to FWD’s earnings and value, and under the ESR regime, interest rates, asset valuation, insurance liability valuation and capital eligibility have a more direct effect on the group capital ratio.

For the investment portfolio, FWD’s disclosures do not yet provide all the information bond investors would ultimately want. More granular information is needed by rating bucket, currency, issuer concentration, duration, hedging, Level 3 exposure, related-party and fund exposure, and duration matching against insurance liabilities. The Annual Report provides sensitivities and risk-management policies, but for investment analysis it is necessary to continue tracking how each market stress transmits to LCSM, IFRS earnings, subsidiary dividends and holding-company liquidity. In particular, the 2025 sensitivities show that an interest-rate increase may be slightly positive for PBT while materially negative for OCI-like equity components, so accounting earnings alone should not be used to assess capital resilience.

FWD’s capital indicators are strong, but its substantive credit quality as an insurer is heavily dependent on the quality of investment assets and insurance liabilities. The high LCSM ratio is the starting point, but the key question is how far that ratio declines under different stress scenarios.

6. Structural Considerations for Bondholders

The most important structural point for FWD bondholders is that the issuer, FWD Group Holdings Limited, is a holding company that owns insurance operating subsidiaries. Policyholder obligations, regulatory capital, investment assets and operating cash flows sit mainly at the operating subsidiaries, while GMTN programme debt, subordinated dated capital securities, holding-company costs and group-level refinancing sit at the holding company. Under stress, jurisdiction-specific insurance regulation, policyholder protection, subsidiary dividend restrictions and capital transfer constraints could restrict holding-company creditors’ access to recovery resources.

This structure is also reflected in the rating levels. Moody’s notional insurer financial strength rating is A2, while the holding-company issuer rating is Baa1. At Fitch, the principal operating companies have an IFS rating of A(Strong), while the group IDR is BBB+. The strength of the insurance operating subsidiaries supports holding-company credit, but it is not an explicit guarantee of holding-company debt.

In insurance groups, operating subsidiary assets are first used to meet policyholder obligations and regulatory capital requirements. Net remittances from operating subsidiaries were US$529 million in 2025, showing a remittance track record, but this does not mean remittances can be freely increased across all jurisdictions. In Japan, Thailand, Vietnam, Indonesia, the Philippines and other markets, insurance supervision, solvency, capital transfer rules, taxation and foreign-exchange regulations need to be reviewed.

For bond investors, differences between security classes are also important. The securities issued by FWD in September 2025 are not senior unsecured bonds, but subordinated dated capital securities. They are expected to qualify as Tier 2 group capital and have mandatory distribution deferral at maturity, regulatory conditions for redemption and subordinated ranking. Even if the insurance operating subsidiaries have strong insurance financial strength, investors in subordinated capital securities take loss-absorption, distribution-deferral and redemption-restriction risks that differ from those borne by senior bond investors.

In analysing FWD’s structure, it is necessary to distinguish between the insurance financial strength of the operating subsidiaries, the issuer credit quality of the holding company and the ranking/equity-credit features of individual securities. The 2025 subordinated dated capital securities are affected by security-specific terms beyond the holding-company issuer credit profile.

This issuer summary has reviewed the Pricing Supplements and Supplemental Offering Circular, but has not reviewed the final trust deed or all detailed terms. Therefore, for an investment decision on a specific ISIN, it is necessary to check distribution deferral, payment stoppage, redemption, taxation, regulatory capital eligibility, parity obligations, subordination clauses, events of default, liquidation ranking and governing law for that instrument. Even if the issuer credit profile is investment grade, pricing of subordinated capital securities is driven not only by the issuer but also by security-specific terms.

FWD’s group credit is supported by the strength of its operating subsidiaries, but there is structural distance between holding-company creditors and policyholders.

7. Capital Structure, Liquidity and Funding

FWD’s capital structure and liquidity were materially streamlined in 2025. The IPO, issuance of new subordinated dated capital securities and redemption of old subordinated notes and perpetual securities confirmed capital-market access, while leverage declined from 25.5% at end-2024 to 21.3% at end-2025. This is still slightly above the company’s medium-term target of 15-20%, but the direction is positive.

Holding-company liquidity is one of the most important indicators for issuer credit. At end-2025, holding-company liquidity resources were US$1,612 million and the undrawn committed RCF was US$1,385 million. The next loan maturity is in 2028 and the next bond maturity is in 2031, so no large near-term maturity concentration is evident. However, liquidity will change depending on subsidiary remittances, interest payments, operating expenses, dividends, growth investment, capital injections and regulatory capital requirements.

As a bridge to repayment resources, 2025 net remittances of US$529 million are the entry point for the annual flow supporting holding-company interest payments, operating expenses and capital needs. Against this, holding-company liquidity resources of US$1,612 million and the undrawn RCF of US$1,385 million together form a liquidity defence line of roughly US$3.0 billion. Compared with borrowings of US$3,046 million, the defence line is substantial, although it does not mean all borrowings are continuously covered by cash. With the next loan maturity in 2028 and the next bond maturity in 2031, near-term maturity risk appears limited. However, this report has not been able to examine annual interest expense, holding-company costs, capital injections into subsidiaries, shareholder distributions or the linkage to statutory profits. Therefore, the appropriate current liquidity assessment is that there is a sufficient defence line against near-term maturities, but analysis of annual cash uses and subsidiary-level distributable amounts remains incomplete.

In the 2025 capital restructuring, FWD redeemed old US$900 million subordinated notes and US$750 million perpetual securities, and issued US$575 million of subordinated dated capital securities due 2030 and US$575 million of subordinated dated capital securities due 2035. Tidying up the old large subordinated and perpetual securities is positive, but the new securities are also subordinated and have regulatory capital features, so this was not a replacement with senior debt.

The decline in leverage is credit positive. However, the 2025 leverage ratio of 21.3% is still slightly above the target range of 15-20%. It will be important to monitor whether improvement stalls because of growth investment, shareholder returns, M&A, capital injections into insurance subsidiaries or additional subordinated debt issuance.

Liquidity is currently strong. Holding-company liquidity of US$1.6 billion, an undrawn committed line of US$1.4 billion and the next maturities falling in 2028 or later reduce near-term refinancing risk. However, if investment asset losses, Japan ESR, higher regulatory capital needs in growth markets, acquisitions and deterioration in medical claims occur at the same time, liquidity uses would increase.

FWD strengthened its holding-company credit profile in 2025, but the stability of issuer credit will continue to depend on subsidiary remittances and market access.

8. Subordinated Securities Analysis

The US$575 million subordinated dated capital securities due 2030 and the US$575 million subordinated dated capital securities due 2035 issued in September 2025 are important for understanding FWD’s issuer credit profile, but they should not be treated as ordinary senior debt. The Pricing Supplements state that these securities are expected to qualify as Tier 2 group capital, with expected ratings of Baa2 from Moody’s and BBB- from Fitch. This reflects security risk below the holding-company issuer rating and the insurance operating subsidiaries’ IFS ratings.

The practical focus is subordination, regulatory capital treatment and distribution deferral. Under the Pricing Supplements, redemption for tax, tax deductibility, rating event, regulatory event, minimum outstanding amount and make-whole redemption are all subject to regulatory redemption conditions. Mandatory Distribution Deferral applies at maturity and distributions are non-compounding. Therefore, even though the coupon is fixed and the securities have stated maturities, investors should not assume the same repayment certainty as senior debt.

The redemption of the old US$900 million subordinated notes and US$750 million perpetual securities is positive in tidying up the capital structure. On the other hand, the new securities are also regulatory capital securities, and redemption decisions under stress could be affected by insurance supervision, capital ratios, ratings, taxation and the availability of replacement capital.

In assessing subordinated capital securities, the issuer’s insurance franchise, LCSM, holding-company liquidity and rating improvement provide support. However, investment analysis needs to centre on the securities’ own Baa2/BBB- level, subordination, distribution deferral and redemption restrictions, rather than the issuer’s Baa1/BBB+ rating. Market price, spread, comparison with similarly rated insurance subordinated debt, tax/hedging and liquidity have not been checked in this report.

FWD’s 2025 subordinated dated capital securities are investment-grade insurance capital instruments supported by issuer improvement, but they are not senior debt. The difference in security class should be reflected in both pricing and risk assessment.

9. Rating Agency View

Rating agency views are an important external check in FWD’s credit analysis. However, ratings should not be used mechanically as one’s own conclusion. In FWD’s case in particular, the insurance financial strength of the operating subsidiaries, the holding-company issuer rating and the ratings of individual subordinated capital securities are different. It is necessary to distinguish the rated entity and the rated security, rather than simply listing rating symbols.

According to the rating discussion in the 2025 Annual Report, Moody’s assigns FWD a notional insurer financial strength rating of A2 and an issuer rating of Baa1 / Stable. The same Annual Report explains that Moody’s upgraded the issuer rating to Baa1 in July 2025. This can be read as reflecting post-listing financial flexibility, capital-market access, leverage improvement and the business franchise. At the same time, the gap between the notional IFS of A2 and the issuer rating of Baa1 shows the structural distance between the insurance financial strength of the operating companies and holding-company creditors. Bond investors should not misread the A2 insurance financial strength as the direct rating of holding-company debt.

For Fitch as well, based on the rating disclosure in the 2025 Annual Report, FWD’s operating entities are treated as having an insurer financial strength rating of A(Strong), while the group issuer default rating is BBB+. The company states that the outlook was revised to Positive in December 2025. Fitch’s rating structure also distinguishes the claims-paying ability of the insurance operating companies from the holding-company issuer credit profile. The A(Strong) IFS of the operating entities indicates strong policyholder payment capacity, but it does not directly guarantee the recovery ranking of holding-company debt or subordinated capital securities.

For the subordinated dated capital securities issued in September 2025, the Pricing Supplements show expected ratings of Baa2 from Moody’s and BBB- from Fitch. These ratings are below FWD’s issuer rating and reflect subordination and capital features. When evaluating FWD’s capital securities, investors need to look not only at the group’s investment-grade status, but also at the notching of the securities themselves.

The positive rating points are that the 2025 listing, deleveraging, capital restructuring, high LCSM and business growth are beginning to feed through to an improved holding-company credit profile.

The rating constraints are the holding-company structure, exposure to growth markets, short post-listing track record, leverage, insurance liability and investment asset risks, and regional differences in profitability. There is room for rating improvement, but rapid migration to a materially higher rating should not be assumed.

This report has not obtained the full latest Moody’s and Fitch reports. Rating levels and 2025 rating actions have been organised based on the company’s Annual Report, while expected ratings for individual securities are based on the Pricing Supplements. As of 13 May 2026, a review of the full rating agency reports to confirm whether any rating changes had occurred after the Annual Report 2025 disclosure remains pending. In the next update, it would be preferable to directly confirm the rating agencies’ upgrade and downgrade triggers, leverage thresholds, capital adequacy assessment, earnings quality and remittance assumptions.

10. Credit Positioning

FWD’s credit positioning needs to be assessed along three axes: Asian insurance group, financial holding company and issuer of subordinated capital securities. As a life insurance franchise, FWD is a growth-oriented insurance group spanning multiple Asian markets, with more regional diversification and capital-market access than a mid-sized single-country insurer. At the same time, compared with large pan-Asian insurers such as AIA and Prudential, which have long listed track records and high earnings stability, FWD still differs in terms of post-listing track record, earnings depth and the assessment of holding-company debt. Based only on confirmed figures, FWD is a growth group with a CSM balance of US$6.6 billion, EV of US$6.9 billion and CTE of US$8.7 billion. It still trails larger listed pan-Asian insurers in absolute scale and public track record, but has more market diversification and capital-market access than a single-country insurer.

Compared with a single-country life insurer, FWD has broader growth potential. A large domestic insurer such as Muang Thai Life is supported by its domestic market and specific bank/shareholder relationships, while FWD has a portfolio across 10 markets. This is positive as geographic diversification, but it also increases regulatory, remittance, currency, product and ALM complexity. FWD’s advantages over a single-country insurer are that economic cycles, interest rates and distribution regulation are not concentrated in one country, it has external capital access through its Hong Kong listing, and it can capture new business growth in multiple markets. Its weaknesses are that the paths for moving capital from each national subsidiary to the holding company are complex, and investors need to track country-level statutory profit and solvency. FWD should not be viewed as “safe because it is large,” but rather as “reducing single-market risk by bundling multiple growth markets, while increasing management complexity.”

As a financial holding company, FWD supports holding-company debt using the financial strength of insurance operating subsidiaries. In this respect, as with bank holding companies and securities holding companies, the earnings, dividends and capital of operating subsidiaries form the foundation of issuer credit. However, in the case of insurers, policyholder protection and regulatory capital have a stronger effect, so subsidiary assets do not automatically become recovery resources for holding-company creditors. FWD’s holding-company credit should be viewed below the insurance operating companies’ IFS, and the rating structure is consistent with that premise.

As subordinated capital securities, FWD’s 2030/2035 securities are investment-grade insurance capital instruments supported by issuer improvement. Compared with senior debt, they have subordination, regulatory capital features, distribution deferral and redemption restrictions. The issuer’s insurance franchise and LCSM provide support, but the notching difference for the security class should not be overlooked. Investors assessing these securities need to compare them with similarly rated insurance Tier 2 instruments, Asian financial institution Tier 2 instruments, Hong Kong-listed insurance groups and BBB/Baa2 securities of similar maturities.

Market spreads and live prices have not been checked in this report. In the normal working environment for this project, Bloomberg, real-time bond prices, OAS and trading levels are not available. Therefore, this report does not conclude whether the bonds are cheap, expensive, a buy, a sell or a hold. From a fundamental standpoint, FWD can be positioned as an “investment-grade insurance holding company on an improving trajectory,” while its subordinated capital securities should be viewed as names where both issuer improvement and security subordination need to be reflected in pricing.

The positive case for FWD rests on the 2025 listing, strong new business growth, growth in CSM and EV, 265% LCSM, holding-company liquidity, deleveraging and improved Moody’s/Fitch assessments. The cautious case rests on the holding-company structure, short earnings track record, regional margin deterioration, the decline in capital after Japan ESR, sensitivities of insurance liabilities and investment assets, subordinated securities terms and subsidiary remittance constraints. The credit position sits in an intermediate area: it has strong growth and investment-grade support, but stability comparable to the highest-quality insurance groups has not yet been fully established. For the 2030/2035 subordinated securities, the practical comparison should be as Baa2/BBB- Tier 2 capital securities rather than as the same credit as the Baa1/BBB+ issuer.

11. Key Credit Strengths and Constraints

FWD’s strengths are its insurance franchise across 10 Asian markets, growth in 2025 APE, new business CSM and VNB, CSM balance of US$6.6 billion, EV of US$6.9 billion, CTE of US$8.7 billion, LCSM PCR of 265%, holding-company liquidity of US$1.6 billion, undrawn RCF of US$1.4 billion and post-listing capital-market access. These indicate that the company is not a peripheral insurer, but has meaningful distribution capability, a stock of future earnings, capital headroom and refinancing capacity.

The constraints are the holding-company structure, short post-listing track record, regional profitability differences, investment assets and insurance liabilities, and the ranking of subordinated capital securities. The insurance financial strength of the operating subsidiaries is high, but holding-company creditors depend on subsidiary remittances. Hong Kong and Macau are driving growth, while Thailand & Cambodia and Japan show pressure on VNB and OPAT. Financial investments of US$52.2 billion and insurance contract liabilities of US$49.7 billion are affected by interest rates, credit spreads, equities, foreign exchange, guaranteed rates, lapses and claims. The 2030/2035 securities have investment-grade expected ratings, but they are not senior debt; they have distribution deferral, redemption restrictions, liquidation subordination and Tier 2 capital features. A conservative assessment of FWD should emphasise capital quality, remittance capacity and security ranking more than sales growth.

12. Downside Scenarios and Monitoring Triggers

FWD’s realistic downside is more likely to appear through a combination of investment assets, products and insurance liabilities, regional growth, regulatory capital and capital-market access than through a single event. The 2025 sensitivities show that a 10% decline in equities would reduce PBT by US$125 million and CSM by US$136 million, while a 50bp increase in interest rates would reduce the LCSM PCR by 14ppt. If growth in Hong Kong and Macau slows and VNB declines continue in Thailand & Cambodia and Japan, the group’s overall new business value may be weaker than the headline figures suggest. If Japan ESR, subsidiary capital requirements, dividend regulation and claims deterioration occur together, remittances to the holding company may also be constrained. In a turbulent capital-market environment, refinancing costs for BBB/Baa insurance holding companies and subordinated capital securities could rise.

Monitoring should cover not only APE, but also new business CSM, VNB, CSM release, OPAT, NPAT, net remittances, LCSM free surplus, LCSM sensitivities and leverage together. Declining VNB margins, slower growth in the CSM balance, further decline in the capital ratio after Japan ESR, decreases in holding-company liquidity or subsidiary remittances, and deviation from the leverage target range would be signals to take a more cautious credit view.

13. Credit View and Monitoring Focus

At present, FWD can be assessed as an investment-grade Asian insurance holding company, with insurance operating subsidiaries assessed around the A/A2 level for insurance financial strength and a holding-company issuer rating supported at the Baa1/BBB+ level. The direction of credit quality is one of gradual improvement, supported by the 2025 listing, deleveraging, growth in CSM and EV, and maintenance of holding-company liquidity. Given the decline in capital headroom after Japan ESR, regional margin differences, insurance liability and investment asset risks, and the ranking difference of subordinated securities, the probability of a sharp near-term move to a higher rating category appears limited. However, a combination of investment asset stress and subsidiary remittance constraints could shift the trajectory negative.

The factors supporting FWD’s credit quality are its insurance franchise across multiple Asian markets, new business growth in 2025, expansion in the CSM balance, high LCSM, holding-company liquidity and rating improvement. Growth in Hong Kong and Macau lifted group APE, new business CSM and VNB, while improvement in CSM release and OPAT indicates that sales growth is beginning to convert into future earnings. Holding-company liquidity of US$1.6 billion, an undrawn RCF of US$1.4 billion, the next loan maturity in 2028 and bond maturity in 2031 also reduce near-term refinancing risk. However, annual interest expense, holding-company costs, statutory profit and subsidiary-level distributable amounts have not been fully analysed, so the defence line against near-term maturities and long-term self-sustaining repayment capacity should be distinguished.

The constraints are the structure as an insurance holding company, the short earnings track record, asset-liability risks and regional dispersion. CSM, EV and CTE are important value indicators, but they are not immediate sources of interest or principal repayment. The pro forma LCSM PCR of 210% after Japan ESR still indicates adequate capital headroom, but capital surplus is compressed relative to the 265% headline ratio. Given insurance liabilities of US$49.7 billion and financial investments of US$52.2 billion, interest rates, credit spreads, equities and funds, medical claims, lapses and reinsurance require continuous monitoring.

By security, the issuer credit profile that is broadly senior-equivalent should be distinguished from the risk of subordinated dated capital securities. FWD’s 2030/2035 securities are supported by the issuer’s investment-grade credit and capital-market access, but they have subordination and capital features, and their expected ratings are Baa2/BBB-. Therefore, assessing these securities requires checking not only that FWD is growing, but also LCSM, regulatory approval, distribution deferral, redemption economics and relative pricing versus similarly rated insurance subordinated bonds.

Going forward, the focus should be on the repeatability of earnings and remittances in post-listing results, actual capital ratios after the introduction of Japan ESR, the sustainability of Hong Kong and Macau growth, profitability improvement in Thailand & Cambodia and Emerging Markets, and the terms, trading spreads and redemption expectations for the 2030/2035 subordinated capital securities.

The practical conclusion at this point is that FWD should be monitored as an “investment-grade Asian insurance holding company on an improving trajectory.” This assessment depends on not confusing the financial strength of the insurance operating subsidiaries with holding-company debt, not treating CSM/EV as immediate cash, and not treating subordinated capital securities as equivalent to senior debt. For an investment decision, this issuer credit assessment needs to be supplemented with separate checks on individual security prices, terms, liquidity, peer comparison and hedging costs.

Short Summary & Conclusion

FWD Group Holdings is an insurance holding company with a Hong Kong-listed pan-Asian life and health insurance group. Its issuer credit profile is improving, supported by the 2025 IPO, CSM/EV growth, LCSM capital headroom and deleveraging. Credit support comes from the insurance franchise across 10 Asian markets and holding-company liquidity, but the insurance financial strength of the operating subsidiaries, holding-company debt and the risk of subordinated dated capital securities need to be assessed separately. The main points to watch are capital headroom after Japan ESR, reliance on Hong Kong and Macau for growth, ALM for investment assets and insurance liabilities, subsidiary remittances, and distribution/redemption terms for subordinated securities.

14. Sources

Primary Sources

• FWD Group Holdings Limited, Annual results for the year ended 31 December 2025, published 2026-03-16, accessed 2026-05-13.
  https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0316/2026031600101.pdf
• FWD Group Holdings Limited, 2025 Annual Report, published 2026-04-16, accessed 2026-05-13.
  https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0416/2026041600073.pdf
• FWD Group Holdings Limited, Supplemental Offering Circular, dated 2025-09-10, published through HKEX 2025-09-11, accessed 2026-05-13.
  https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0911/2025091100179.pdf
• FWD Group Holdings Limited, Pricing Supplements for US$575,000,000 5.252% Subordinated Dated Capital Securities due 2030 and US$575,000,000 5.836% Subordinated Dated Capital Securities due 2035, dated 2025-09-15, published through HKEX 2025-09-23, accessed 2026-05-13.
  https://www.hkexnews.hk/listedco/listconews/sehk/2025/0923/2025092300262.pdf

Rating Sources

• FWD Group Holdings Limited Annual Report 2025 rating discussion, used for company-disclosed Moody’s and Fitch ratings and 2025 rating-action descriptions, accessed 2026-05-13.
• FWD Group Holdings Limited Pricing Supplements, expected issue ratings from Moody’s and Fitch, accessed 2026-05-13.

Internal Working Data

• issuer_summary/issuers/fwd/working/fwd_20260513_writing_plan.md
• issuer_summary/issuers/fwd/data/fwd_key_metrics_20260513.json

Unverified / Pending

• Live bond prices, yields, spreads, OAS, trading liquidity and relative value versus Asian insurance Tier 2 or similarly rated financial subordinated bonds.
• Full trust deed and final legal terms for the 2030 and 2035 subordinated dated capital securities, including all default, subordination, tax and regulatory-capital provisions beyond the Pricing Supplements reviewed.
• Subsidiary-by-subsidiary solvency, distributable profit, statutory profit, free surplus reconciliation, remittance restrictions and local regulatory capital buffers.
• Investment portfolio by full rating bucket, currency, duration, issuer concentration, hedge profile, Level 3 assets and fund liquidity.
• Insurance liability details including guarantee rates, asset-liability duration gap, lapse / persistency, claims ratios, reinsurance and rate repricing flexibility.
• More detailed rating agency reports from Moody’s and Fitch, including upgrade and downgrade sensitivities after the 2025 IPO and debt refinancing, and confirmation of any rating changes after the Annual Report 2025 disclosure.